Up to three-quarters of patients quit injectable GLP-1 therapy within a year, and gastrointestinal side effects are the single most-cited reason why. Phase 2 results for the amylin analogue petrelintide, published in The Lancet Diabetes & Endocrinology, show a drug that delivers double-digit weight loss while keeping nausea rates closer to placebo than to incretin therapy.1
Amylin is a pancreatic hormone that regulates appetite through pathways that run largely independent of the incretin system GLP-1 drugs exploit. That distinction matters clinically: real-world data suggest roughly 37% of semaglutide discontinuations in a cardiovascular outcomes trial were driven by gastrointestinal adverse events alone, and stopping treatment tends to bring the weight back.1
Petrelintide is one of several long-acting amylin analogues now in development, alongside cagrilintide and eloralintide. The phase 2 trial behind this week's data enrolled 714 people across 32 sites in the United States, Poland and Romania between December 2024 and February 2025, randomizing 485 of them to once-weekly petrelintide at 1.0mg, 2.5mg, 5.0mg, 7.0mg or 9.0mg, or to placebo.1
The Numbers
By week 42, mean weight loss ranged from 8.7% at the lowest dose to 10.7% at 5.0mg, with the two higher doses landing close behind at 10.5% and 10.2%. Placebo produced 1.7% loss. Every active dose from 2.5mg upward converged in a tight band around 9-11%, a flatter dose-response curve than GLP-1 trials typically show.1
Tolerability is where petrelintide separates from the incretin class. Nausea affected 20% of participants on active treatment against 6% on placebo, a gap far narrower than the 20-to-40-point spreads reported for semaglutide and tirzepatide trials. Vomiting was actually less frequent with petrelintide, 3%, than with placebo, 6%. Diarrhoea matched placebo at 7%, and constipation ran only slightly ahead, 7% versus 4%.
The discontinuation data reinforce the same pattern. Only 1.5% of participants permanently stopped petrelintide because of gastrointestinal adverse events, and 2.2% needed a dose reduction for that reason. Between 88% and 98% of participants successfully escalated to one of the three highest maintenance doses, all of which produced similar weight loss by week 42.
Petrelintide also improved blood pressure, LDL cholesterol, triglycerides and C-reactive protein, a marker of systemic inflammation, echoing the cardiometabolic benefits seen with GLP-1 therapy despite the different mechanism. Eighteen serious adverse events occurred across the trial, evenly split between petrelintide (3%) and placebo (4%), with no death reported and no dose-related pattern.
The headline weight-loss number for petrelintide, 10.7% at best, will read as modest next to the 15-20% routinely reported for tirzepatide and now retatrutide. That comparison misses the actual clinical question this trial answers: what happens to the roughly one in three to four patients who cannot tolerate an incretin drug long enough to reach those numbers in the first place. For that population, a drug that stays close to placebo on nausea and vomiting while still producing meaningful weight loss is not a consolation prize, it is the difference between a treatment a patient actually stays on and one they quietly stop filling.
Zealand Pharma funded the trial and will need phase 3 data before petrelintide reaches prescribers, so nothing here changes practice today. But the tolerability signal is specific and consistent enough, across nausea, vomiting, discontinuation and dose-escalation success, that it is worth flagging to patients now weighing whether to start or continue a GLP-1 drug: a materially different option is moving through the pipeline.
The linked commentary from Madsbad and Holst points toward where this likely goes next: combination therapy. Cagrilintide paired with semaglutide already exists in trials, and a unimolecular dual agonist hitting both the GLP-1 and amylin receptors, zenagamtide, is in development as both an injection and an oral formulation. Whether combining mechanisms compounds the side-effect burden or preserves petrelintide's tolerability advantage is, per the commentators' own admission, still an open question the cagrilintide-semaglutide data has not settled either way.
For now, amylin-class monotherapy reads as a plausible first-line option specifically for patients prioritising tolerability over maximum weight loss, not a replacement for incretin therapy across the board. The mechanism is different enough, and the safety data consistent enough, to earn that distinct place rather than being filed as simply a weaker GLP-1 alternative.
Phase 3 trials will need to confirm this tolerability advantage holds at scale and over a longer duration than 42 weeks, and regulators will want to see whether the flatter dose-response curve observed here means most patients can stay on a mid-range dose without chasing the marginal gains that push GLP-1 prescribing toward maximum tolerated doses. Until then, petrelintide belongs in the conversation as a genuine mechanism-distinct alternative, not yet a prescribing decision.
- The Pivot Petrelintide, an amylin analogue, delivers double-digit weight loss through a mechanism independent of the incretin pathway GLP-1 drugs use, with markedly better gastrointestinal tolerability.
- The Data Weight loss reached 10.7% at 42 weeks versus 1.7% with placebo, while nausea affected 20% of participants versus 6% on placebo, a fraction of the gap seen in GLP-1 trials.
- The Action Consider amylin-class therapy as a realistic option for patients who have discontinued or avoided GLP-1 drugs specifically because of gastrointestinal intolerance, pending phase 3 confirmation.
ART-2026-1885
·09/26
Drafted with AI assistance, reviewed and approved by the editorial team. This publication is intended for healthcare professionals, researchers, and life science industry professionals. Content is provided for informational and educational purposes only and does not constitute medical advice.
Cite This Article
Team E. Petrelintide trades some weight loss for a lot less nausea. The Life Science Feed. Published September 29, 2026. Updated September 29, 2026. Accessed September 29, 2026. https://thelifesciencefeed.com/endocrinology/obesity/research/petrelintide-amylin-obesity-tolerability-weight-loss.
Editorial & AI Standards
All content is researched from peer-reviewed, open-access sources: published trial data, clinical guidelines, and regulatory filings. AI tools are used solely to structure and summarise that evidence; no AI-generated conclusions appear without editor verification against the primary source.
Every article is reviewed by a named editor before publication. Source citations are listed in the References section. This content does not represent the views of any pharmaceutical company, medical device manufacturer, or healthcare provider.
Licence & Rights
© 2026 The Life Science Feed. All rights reserved. Unless otherwise indicated, all content is the property of The Life Science Feed and may not be reproduced, distributed, or transmitted in any form or by any means without prior written permission.
Medical Disclaimer
The information provided on The Life Science Feed is for educational and informational purposes only. It is not intended as a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified healthcare provider regarding any medical condition or treatment decision. Never disregard professional medical advice or delay in seeking it because of something you have read on this website.
References
1. Garvey WT, et al. Efficacy and safety of once-weekly petrelintide for obesity: a phase 2, randomised, placebo-controlled trial. Presented at: European Association for the Study of Diabetes (EASD) Annual Meeting; September 28-October 2, 2026; Milan, Italy. Forthcoming in The Lancet Diabetes & Endocrinology. Available from: https://www.thelancet.com/journals/landia/article/PIIS2213-8587(26)00213-5/fulltext
2. Madsbad S, Holst JJ. Comment on: Efficacy and safety of once-weekly petrelintide for obesity. Presented at: European Association for the Study of Diabetes (EASD) Annual Meeting; September 28-October 2, 2026; Milan, Italy. Forthcoming in The Lancet Diabetes & Endocrinology. Available from: https://www.thelancet.com/journals/landia/article/PIIS2213-8587(26)00216-0/fulltext
